ArticleJournal of neuro-oncology2026
Microsurgical outcomes and prognostic analysis of cerebellar gliomas; pathology, molecular biomarkers, and novel clinical insights: a retrospective study.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCerebellar gliomas are a descriptive subset of posterior fossa gliomas which presents unique clinical challenges due to their proximity to critical structures.
objectiveTo establish a location-stratified, molecularly integrated clinical benchmark for posterior fossa gliomas (cerebellar gliomas as a descriptive subset), and to define subtype-specific pathways that address the unique biological and anatomical characteristics of these tumors, distinct from supratentorial glioma paradigms. This study sets location-specific microsurgical outcome evaluation as primary objective and independent prognostic factor identification and subtype-specific adjuvant therapy definition as secondary objective.
methodsThis retrospective analysis of 450 patients with posterior fossa gliomas (cerebellar gliomas) who underwent microsurgical resection at a single institution was performed between 2014 and 2024. Anatomical localization such as cerebellar hemisphere, vermis, fourth ventricle, cerebellopontine angle (CPA) region, tumor volumetrics, extent of resection, and molecular profiling such as IDH1/2, 1p/19q, MGMT, TERT, and BRAF V600E, as well as perioperative morbidity, and long-term survival were systematically correlated. 1:1 propensity score matching (PSM) was used to disentangle the causal effect of gross total resection (GTR) from tumor biology/anatomical confounding.
resultsGross total resection (GTR) was achieved in 74.9% of patients, with location emerging as the dominant surgical predictor: cerebellar hemisphere (80.7%) > vermis (78.0%) > fourth ventricle (58.2%) > CPA region (42.1%) (P < 0.001). In the subgroup of CPA region patients who received the modified retrosigmoid approach, GTR rate was significantly improved to 57.1% (8/14), yielding a 3-year overall survival of 67.3% to a ≥ 25% absolute improvement over historical controls. Molecular correlations in cerebellar gliomas diverged from supratentorial patterns: the canonical inverse IDH-TERT correlation was negligible (r = -0.09 vs. r ≈ -0.7 in supratentorial tumors), and IDH mutation showed only weak positive correlation with 1p/19q codeletion (r = 0.19, P < 0.001).
conclusionCerebellar gliomas follow the principle that location and molecular biomarkers are complementary core prognostic factors, with location as an independent determinant of surgical feasibility and long-term survival. Surgical tailoring to brainstem-adjacent anatomy and molecularly guided adjuvant strategies—including early irradiation for IDH-wildtype LGGs and intensified systemic therapy for TERT-mutant HGGs—deliver meaningful survival gains.
Indexed as
Identifiers
41981289What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.